Moderna (MRNA)
(Delayed Data from NSDQ)
$122.50 USD
+1.36 (1.12%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $122.44 -0.06 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$122.50 USD
+1.36 (1.12%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $122.44 -0.06 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Zacks News
The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals
Will Moderna Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Moderna.
Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio
by Zacks Equity Research
The biotech sector was in focus with pipeline updates from a few small biotech companies.
4 Healthcare Stocks to Gain as Coronavirus Threat Looms Large
by Zacks Equity Research
Healthcare companies are trying to find a cure and contain the coronavirus outbreak. This keeps the industry in focus
Moderna (MRNA) Beats Earnings Estimates in Q4, Revenues Miss
by Zacks Equity Research
Moderna (MRNA) reports narrower-than expected loss in the fourth quarter. However, revenues miss estimates. Stock up.
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Progress of its pipeline candidates is likely to have increased Moderna's (MRNA) operating expenses in the fourth quarter.
What's in Store for Vertex in 2020 After a Remarkable 2019?
by Kinjel Shah
In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
J&J (JNJ) Signs Deal With HHS to Develop Coronavirus Vaccine
by Zacks Equity Research
Johnson & Johnson (JNJ) expands its agreement with BARDA, part of U.S. Department of Health and Human Services for accelerated development of a vaccine for the newly found coronavirus.
Inovio Gets FDA Nod to Begin Study on INO-3107, Stock Gains
by Zacks Equity Research
The FDA accepts Inovio's (INO) IND application for INO-3107 to initiate a phase I/II study for the treatment of recurrent respiratory papillomatosis, a rare disease caused by HPV. Stock up.
Can Biotech ETFs Continue to Soar in 2020?
by Neena Mishra
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
Should Growth Investors Buy this Cancer Screening Biotech Stock?
by Benjamin Rains
Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $20.38 in the latest trading session, marking a -0.63% move from the prior day.
J&J (JNJ) Plans to Develop Vaccine for New Coronavirus
by Zacks Equity Research
J&J (JNJ) is looking to develop a vaccine for the new coronavirus infection. Its drug Erleada's label is expanded to include new prostate cancer patient population in Europe.
Coronavirus: How Fast to 100,000 Infected?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Coronavirus: Epidemic or Pandemic?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Implied Volatility Surging for Moderna (MRNA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Wining & Losing ETF Areas on Coronavirus Outbreak
by Sanghamitra Saha
Coronavirus outbreak puts these ETF areas in winning and losing positions.
Coronavirus Spooks Global Markets: Winners and Losers
by Zacks Equity Research
So far, 18 fatalities and more than 600 are affected by coronavirus in China and the virus is spreading across the boundary, spooking investors.
CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs
by Indrajit Bandyopadhyay
Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.
Company News for Jan 23, 2020
by Zacks Equity Research
Companies in the news are: FSB, AKCA, ALLY, MRNA
3 Biotech Stocks Likely to Gain as Coronavirus Spreads
by Zacks Equity Research
Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.
Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
The Zacks Analyst Blog Highlights: Alteryx, Moderna, Car-Mart, Bloom Energy and Target
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alteryx, Moderna, Car-Mart, Bloom Energy and Target